CN103990177A - Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide - Google Patents
Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide Download PDFInfo
- Publication number
- CN103990177A CN103990177A CN201410181123.XA CN201410181123A CN103990177A CN 103990177 A CN103990177 A CN 103990177A CN 201410181123 A CN201410181123 A CN 201410181123A CN 103990177 A CN103990177 A CN 103990177A
- Authority
- CN
- China
- Prior art keywords
- mesoporous silicon
- medicine
- active polypeptide
- protein active
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
A preparation method for a mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide comprises: dispersing mesporous silicon into an organic solvent, adding a silane coupling agent 3- aminopropyltriethoxysilane, mixing and reacting to obtain aminated mesoporous silicon; utilizing a cross-linking agent to perform covalent grafting on bone-morphogenetic-protein active polypeptide and aminated mesoporous silicon; utilizing a cross-linking agent to react polyethylene glycol monocarboxylic acid with residual amino on mesoporous silicon; and loading with medicine molecules capable of realizing induction ossification. The method is easy to operate, simple in equipment and mild in reaction conditions, and price is low. The prepared mesoporous silicon medicine-carrying particles are good in dispersibility, good in stability and good in biological compatibility. The medicine-carry system comprises bone-morphogenetic-protein active polypeptide and the medicine molecules both containing bone induction activity, and is applicable to bone defect restoration.
Description
Technical field
The invention belongs to the preparation field of bone renovating material, the preparation method of the mesoporous silicon medicine-carried system that particularly a kind of bone morphogenetic protein active polypeptide is modified.
Background technology
Bone is histoorgan hard in human body, is bearing the important duty of motion, support and protection health.According to estimates, China is every year because the reason such as skeleton trauma, spinal column degenerative disease, neoplastic bone excision causes due to vehicle accident and work safety accident bone is damaged or dysfunction has millions of crowds.Therefore, bone is damaged becomes a kind of common disease of bone in daily curative activity.
At present, osseous tissue transplanting and artificial bone repair materials are the primary treatment means that bone tissue restoration adopts.Wherein, artificial bone repair materials not only can overcome the autologous bone transplanting limited defect of originating, and can also solve the danger such as immunological rejection and potential source of disease propagation existing after allogenic bone transplantation.And bioactie agent is combined with material, can give the better biological activity of material and stronger bone repair ability, be one of bioactive important means of regulation and control bone renovating material.Knownly can promote osteogenetic bioactie agent to have bone morphogenetic protein (BMP-2,4,6,7 and 9 etc.), insulin like growth factor, platelet-derived growth factor and β-transforming growth factor and drug molecule etc.In these bioactie agents, bone morphogenetic protein is considered to bone reparation and the most important active factors of osteanagenesis.In addition, 2 kinds or bioactie agent of more than two kinds are combined to use, can obtain the induced osteogenesis differentiation stronger compared with monofactor.
But, natural bmp protein limited amount, complex structure, and be degraded rapidly in vivo.BMP is as a kind of exogenous growth factor, and the half-life is in vivo very short, and the effect of body endoenzyme can make its inactivation, has limited its extensive use.Meanwhile, research shows, the BMP-2 of high concentration can cause (Injury, 2009,40, S32-S38) such as vertebral body osteosis, myeloradiculitis and cervical spine soft tissue swelling.There are some researches show, the Core Feature region amino acid sequence of BMP has induced osteogenesis function equally.As deriving from the aminoacid sequence of 73-92 in BMP-2, the discoveries such as Saito there is the l cell C3H10T1/2 Osteoblast Differentiation of promotion (BBA-Proteins Proteomics, 2003,1651,60-67).Therefore, will derive from bioactie agent and there is bioactive aminoacid sequence and be combined with material, can prepare the bone renovating material with high induced activity.
In recent years, mesoporous material has caused the broad interest of researcher for the preparation of bone renovating material.Wherein, silicon-based mesoporous material has obtained preliminary progress in the bone field of repairing, as mesopore bioactive glass, mesoporous silicon based xerogel and mesoporous silicon.
Transmit the plasmid DNA of expressed BMP-2 as Kim etc. utilizes amination mesoporous silicon, promote mescenchymal stem cell to osteoblast differentiation (J.Biomed.Mater.Res., 2013,101A, 1651-1660).
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of preparation method of mesoporous silicon medicine-carried system of bone morphogenetic protein active polypeptide modification, the method easy operating, and equipment is simple, and reaction condition gentleness is cheap; The mesoporous silicon medicine carrying particle good dispersion of preparation, good stability, and there is good biocompatibility.
The preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide of the present invention is modified, comprising:
(1) mesoporous silicon nanoparticle is scattered in organic solvent, then adds 3-aminopropyl triethoxysilane, under 40-80 DEG C of condition, reaction 6-12h, centrifugal, washing, obtains amination mesoporous silicon; Then amination mesoporous silicon is added in solvent, disperse, obtain amination mesoporous silicon nano-particle solution; The mass ratio of mesoporous silicon nanoparticle, 3-aminopropyl triethoxysilane is 1:0.5-1:2;
(2) bone morphogenetic protein active polypeptide is dissolved in solvent, then adds 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides EDC and N-hydroxy-succinamide NHS, under room temperature condition, reaction 10-30min;
(3) amination mesoporous silicon nano-particle solution is added in step (2), under nitrogen protection, stirring at room temperature reaction 24-48h, centrifugal, washing, dry, obtain peptide modified mesoporous silicon nanoparticle, then be dissolved in solvent, obtain peptide modified mesoporous silicon nano-particle solution;
(4) Polyethylene Glycol monocarboxylic acid is dissolved in solvent, adds 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides EDC and N-hydroxy-succinamide NHS, room temperature reaction 10-30min;
(5) the peptide modified mesoporous silicon nano-particle solution in step (3) is added in step (4), under nitrogen protection, stirring at room temperature reaction 24-48h, centrifugal, washing, dry, obtain polyethyleneglycol modified mesoporous silicon nanoparticle; Wherein the mass ratio of amination mesoporous silicon nanoparticle and bone morphogenetic protein active polypeptide, Polyethylene Glycol monocarboxylic acid is 100-500:1:40;
(6) above-mentioned polyethyleneglycol modified mesoporous silicon nanoparticle is scattered in solvent, then adds in drug solution, stirring at room temperature 12-24h, centrifugal, washing, dry, obtain medicine-carried nano particles.
Described step (1) organic solvent is the one in ethanol, methanol, acetone.
In described step (1), the concentration of amination mesoporous silicon nano-particle solution is 100-500mg/ml.
In described step (2), bone morphogenetic protein active polypeptide derives from one or more in BMP-2, BMP-4, BMP-6, BMP-7, BMP-9.
In described step (2), the mol ratio of bone morphogenetic protein active polypeptide, EDC, NHS is 1-5:100:100.
In described step (4), the concentration of polyethyleneglycol carboxylic acid solution is 1-5mg/ml.
Described step (6) Chinese medicine is one or more of dexamethasone, Allan sodium phosphate, vitamin D, icariin, danshensu.
The concentration of described step (6) Chinese medicine solution is 0.1-5mg/ml, and the solvent of drug solution is phosphate buffer or ethanol.
Described solvent in described step (1), (2), (4), (6) is phosphate buffer, and pH is 7.0-7.4.
In described step (6), the medicine-carried nano particles of gained is used for inducing mesenchymal stem cell Osteoblast Differentiation as bone impairment renovation material.
Mesoporous silicon nanoparticle prepare reference literature method (J.Am.Chem.Soc., 2004,126,13216-13217), synthesis step is as follows: 1g cetyl trimethyl ammonium bromide (CTAB) is added in the beaker that contains 480ml deionized water, add 3.5ml2mol/L NaOH solution, oil bath temperature control is at 80 DEG C.After solution clarification, add 5ml ethyl orthosilicate (TEOS), react and produce white precipitate after 2 hours.Utilize centrifugal (8000 revs/min) to collect product, and by deionized water and washing with alcohol 3 times.Template CTAB removes by refluxing in methanolic acid solution (160ml methanol and 9ml hydrochloric acid) for 24 hours, more centrifugal, lyophilization, obtains the not mesoporous silicon nanoparticle containing template.
The present invention utilizes mesoporous silicon surface to be easy to modify and strong absorption property characteristic, by at mesoporous silicon surface covalence graft bone morphogenetic protein active polypeptide and Polyethylene Glycol, absorption has the drug molecule of bone-inducting active again, prepares the mesoporous silicon medicine-carried system that bone morphogenetic protein active polypeptide is modified.
beneficial effect
(1) easy operating of the present invention, equipment is simple, and reaction condition gentleness is cheap;
(2) the mesoporous silicon medicine carrying particle good dispersion that prepared by the present invention, good stability also has good biocompatibility; This medicine-carried system contains bone morphogenetic protein active polypeptide and the drug molecule with bone induction, can repair field for bone.
Brief description of the drawings
Fig. 1 is the scanning electron microscope TEM photo of embodiment 1 products therefrom, is (a) the mesoporous silicon nanoparticle TEM photo of embodiment 1 gained, is (b) the co-modified mesoporous silicon TEM photo of BMP-2 polypeptide/Polyethylene Glycol of embodiment 1 gained;
Fig. 2 is the low-angle x-ray diffraction pattern of embodiment products therefrom, (a) be the mesoporous silicon nanoparticle x-ray diffraction pattern of embodiment 1 gained, (b) being the peptide modified mesoporous silicon nanoparticle x-ray diffraction pattern of BMP-2 of embodiment 1 gained, is (c) the co-modified mesoporous silicon nanoparticle x-ray diffraction pattern of BMP-2 polypeptide/Polyethylene Glycol of embodiment 1 gained;
Fig. 3 is the cytotoxicity of the co-modified mesoporous silicon nanoparticle of embodiment 1 products therefrom BMP-2 polypeptide/Polyethylene Glycol to mesenchymal stem cells MSCs.
Detailed description of the invention
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment are only not used in and limit the scope of the invention for the present invention is described.In addition should be understood that those skilled in the art can make various changes or modifications the present invention after having read the content of the present invention's instruction, these equivalent form of values fall within the application's appended claims limited range equally.
Embodiment 1
(1) mesoporous silicon nanoparticle prepare reference literature method (J.Am.Chem.Soc., 2004,126,13216-13217).Synthesis step is as follows: 1g cetyl trimethyl ammonium bromide (CTAB) is added in the beaker that contains 480ml deionized water, add 3.5ml2mol/L NaOH solution, oil bath temperature control is at 80 DEG C.After solution clarification, add 5ml ethyl orthosilicate (TEOS), react and produce white precipitate after 2 hours.Utilize centrifugal (8000 revs/min) to collect product, and by deionized water and washing with alcohol 3 times.Template CTAB removes by refluxing in methanolic acid solution (160ml methanol and 9ml hydrochloric acid) for 24 hours, more centrifugal, lyophilization, obtains the not mesoporous silicon nanoparticle containing template;
(2) the mesoporous silicon nanoparticle of step (1) gained is dispersed in ethanol, adds 3-aminopropyl triethoxysilane, in 80 DEG C of reactions 6 hours, centrifugal collection, ethanol and water washing, obtain amination mesoporous silicon;
(3) the BMP-2 active polypeptide of 2mg is dissolved in phosphate buffer, then add 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides (EDC) and N-hydroxy-succinamide (NHS), under room temperature, react 30 minutes;
(4) the amination mesoporous silicon of being prepared by step (2) joins in phosphate buffer (pH7.4), and ultrasonic being uniformly dispersed obtains the nano-particle solution of 200mg/ml;
(5) nano-particle solution of step (4) is joined in step (3), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains the peptide modified mesoporous silicon nanoparticle of BMP-2 through centrifugal, phosphate buffer washing, vacuum drying;
(6), taking phosphate buffer as solvent, the polyethyleneglycol carboxylic acid solution of preparation 2mg/ml, then adds EDC and NHS, reacts 30 minutes under room temperature;
(7) nanoparticle step (5) being obtained is scattered in phosphate buffer, join again in step (6), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains polyethyleneglycol modified mesoporous silicon nanoparticle through centrifugal, phosphate buffer washing, vacuum drying;
(8) taking phosphate buffer as solvent, the dexamethasone solution of preparation 0.1mg/ml, takes 200mg step (7) products therefrom and is distributed in solvent, then join in drug solution, stirring at room temperature 24 hours, obtains medicine-carried nano particles through centrifugal, washing, vacuum drying.
Embodiment 2
(1) mesoporous silicon nanoparticle prepare reference literature method (J.Am.Chem.Soc., 2004,126,13216-13217).Synthesis step is as follows: 1g cetyl trimethyl ammonium bromide (CTAB) is added in the beaker that contains 480ml deionized water, add 3.5ml2mol/L NaOH solution, oil bath temperature control is at 80 DEG C.After solution clarification, add 5ml ethyl orthosilicate (TEOS), react and produce white precipitate after 2 hours.Utilize centrifugal (8000 revs/min) to collect product, and by deionized water and washing with alcohol 3 times.Template CTAB removes by refluxing in methanolic acid solution (160ml methanol and 9ml hydrochloric acid) for 24 hours, more centrifugal, lyophilization, obtains the not mesoporous silicon nanoparticle containing template;
(2) the mesoporous silicon nanoparticle of step (1) gained is dispersed in ethanol, adds 3-aminopropyl triethoxysilane, in 80 DEG C of reactions 6 hours, centrifugal collection, ethanol and water washing, obtain amination mesoporous silicon;
(3) the BMP-9 active polypeptide of 2mg is dissolved in phosphate buffer, then add 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides (EDC) and N-hydroxy-succinamide (NHS), under room temperature, react 30 minutes;
(4) the amination mesoporous silicon of being prepared by step (2) joins in phosphate buffer (pH7.4), and ultrasonic being uniformly dispersed obtains the nano-particle solution of 200mg/ml;
(5) nano-particle solution of step (4) is joined in step (3), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains the peptide modified mesoporous silicon nanoparticle of BMP-9 through centrifugal, phosphate buffer washing, vacuum drying;
(6), taking phosphate buffer as solvent, the polyethyleneglycol carboxylic acid solution of preparation 2mg/ml, then adds EDC and NHS, reacts 30 minutes under room temperature;
(7) nanoparticle step (5) being obtained is scattered in phosphate buffer, join again in step (6), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains polyethyleneglycol modified mesoporous silicon nanoparticle through centrifugal, phosphate buffer washing, vacuum drying;
(8) taking phosphate buffer as solvent, the alendronic Acid sodium solution of preparation 1mg/ml, takes 200mg step (7) products therefrom and is distributed in solvent, then join in drug solution, stirring at room temperature 24 hours, obtains medicine-carried nano particles through centrifugal, washing, vacuum drying.
Embodiment 3
(1) mesoporous silicon nanoparticle prepare reference literature method (J.Am.Chem.Soc., 2004,126,13216-13217).Synthesis step is as follows: 1g cetyl trimethyl ammonium bromide (CTAB) is added in the beaker that contains 480ml deionized water, add 3.5ml2mol/L NaOH solution, oil bath temperature control is at 80 DEG C.After solution clarification, add 5ml ethyl orthosilicate (TEOS), react and produce white precipitate after 2 hours.Utilize centrifugal (8000 revs/min) to collect product, and by deionized water and washing with alcohol 3 times.Template CTAB removes by refluxing in methanolic acid solution (160ml methanol and 9ml hydrochloric acid) for 24 hours, more centrifugal, lyophilization, obtains the not mesoporous silicon nanoparticle containing template;
(2) the mesoporous silicon nanoparticle of step (1) gained is dispersed in ethanol, adds 3-aminopropyl triethoxysilane, in 80 DEG C of reactions 6 hours, centrifugal collection, ethanol and water washing, obtain amination mesoporous silicon;
(3) the BMP-2 active polypeptide of 4mg is dissolved in phosphate buffer, then add 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides (EDC) and N-hydroxy-succinamide (NHS), under room temperature, react 30 minutes;
(4) the amination mesoporous silicon of being prepared by step (2) joins in phosphate buffer (pH7.4), and ultrasonic being uniformly dispersed obtains the nano-particle solution of 400mg/ml;
(5) nano-particle solution of step (4) is joined in step (3), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains the peptide modified mesoporous silicon nanoparticle of BMP-2 through centrifugal, phosphate buffer washing, vacuum drying;
(6), taking phosphate buffer as solvent, the polyethyleneglycol carboxylic acid solution of preparation 2mg/ml, then adds EDC and NHS, reacts 30 minutes under room temperature;
(7) nanoparticle step (5) being obtained is scattered in phosphate buffer, join again in step (6), under nitrogen protection, stirring at room temperature reaction 24 hours, obtains polyethyleneglycol modified mesoporous silicon nanoparticle through centrifugal, phosphate buffer washing, vacuum drying;
(8) taking phosphate buffer as solvent, the alendronic Acid sodium solution of preparation 2mg/ml, takes 200mg step (7) products therefrom and is distributed in solvent, then join in drug solution, stirring at room temperature 24 hours, obtains medicine-carried nano particles through centrifugal, washing, vacuum drying.
Claims (10)
1. a preparation method for the mesoporous silicon medicine-carried system that bone morphogenetic protein active polypeptide is modified, comprising:
(1) mesoporous silicon nanoparticle is scattered in organic solvent, then adds 3-aminopropyl triethoxysilane, under 40-80 DEG C of condition, reaction 6-12h, centrifugal, washing, obtain amination mesoporous silicon, redispersion, in solvent, obtains amination mesoporous silicon nano-particle solution; Wherein the mass ratio of mesoporous silicon nanoparticle, 3-aminopropyl triethoxysilane is 1:0.5-1:2;
(2) bone morphogenetic protein active polypeptide is dissolved in solvent, then adds 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides EDC and N-hydroxy-succinamide NHS, under room temperature condition, reaction 10-30min;
(3) amination mesoporous silicon nano-particle solution is added in step (2), under nitrogen protection, stirring at room temperature reaction 24-48h, centrifugal, washing, dry, obtain peptide modified mesoporous silicon nanoparticle, then be dissolved in solvent, obtain peptide modified mesoporous silicon nano-particle solution;
(4) Polyethylene Glycol monocarboxylic acid is dissolved in solvent, adds 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimides EDC and N-hydroxy-succinamide NHS, room temperature reaction 10-30min;
(5) the peptide modified mesoporous silicon nano-particle solution in step (3) is added in step (4), under nitrogen protection, stirring at room temperature reaction 24-48h, centrifugal, washing, dry, obtain polyethyleneglycol modified mesoporous silicon nanoparticle; Wherein the quality of amination mesoporous silicon nanoparticle and bone morphogenetic protein active polypeptide, Polyethylene Glycol monocarboxylic acid is 100-500:1:40;
(6) above-mentioned polyethyleneglycol modified mesoporous silicon nanoparticle is scattered in solvent, then adds in drug solution, stirring at room temperature 12-24h, centrifugal, washing, dry, obtain medicine-carried nano particles.
2. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: described step (1) organic solvent is the one in ethanol, methanol, acetone.
3. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: in described step (1), the concentration of amination mesoporous silicon nano-particle solution is 100-500mg/ml.
4. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: in described step (2), bone morphogenetic protein active polypeptide derives from one or more in BMP-2, BMP-4, BMP-6, BMP-7, BMP-9.
5. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: in described step (2), the mol ratio of bone morphogenetic protein active polypeptide, EDC, NHS is 1-5:100:100.
6. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: in described step (4), the concentration of polyethyleneglycol carboxylic acid solution is 1-5mg/ml.
7. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: described step (6) Chinese medicine is one or more of dexamethasone, Allan sodium phosphate, vitamin D, icariin, danshensu.
8. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, it is characterized in that: the concentration of described step (6) Chinese medicine solution is 0.1-5mg/ml, and the solvent of drug solution is phosphate buffer or ethanol.
9. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, it is characterized in that: the solvent described in step (1), (2), (4), (6) is phosphate buffer, pH is 7.0-7.4.
10. the preparation method of the mesoporous silicon medicine-carried system that a kind of bone morphogenetic protein active polypeptide according to claim 1 is modified, is characterized in that: in described step (6), the medicine-carried nano particles of gained is used for inducing mesenchymal stem cell Osteoblast Differentiation as bone impairment renovation material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410181123.XA CN103990177A (en) | 2014-04-29 | 2014-04-29 | Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410181123.XA CN103990177A (en) | 2014-04-29 | 2014-04-29 | Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103990177A true CN103990177A (en) | 2014-08-20 |
Family
ID=51304672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410181123.XA Pending CN103990177A (en) | 2014-04-29 | 2014-04-29 | Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103990177A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106519558A (en) * | 2016-10-11 | 2017-03-22 | 天津大学 | Preparation and application of imidozalium salt type polyether ether ketone/functionalized mesoporous silicon hybrid membrane |
| CN106729941A (en) * | 2017-03-07 | 2017-05-31 | 南京林业大学 | A kind of preparation method of chitosan-based sponge dressing |
| CN106806939A (en) * | 2017-03-29 | 2017-06-09 | 中国人民解放军国防科学技术大学 | Bone renovating material and its preparation method and application |
| CN110433331A (en) * | 2019-08-26 | 2019-11-12 | 四川大学 | A kind of bioactive bracket and preparation method thereof |
| CN115010904A (en) * | 2022-07-04 | 2022-09-06 | 青岛爱尔家佳新材料股份有限公司 | Organosilicon modified waterborne epoxy emulsion, waterborne epoxy primer and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721751A (en) * | 2008-10-10 | 2010-06-09 | 张阳德 | Human tissue engineering support loaded with controlled-release cell growth factor and provided with hollow silicon dioxide ball with kernel and preparation method and applications thereof |
| CN101721970A (en) * | 2008-10-22 | 2010-06-09 | 中国科学院大连化学物理研究所 | Method for preparing modification functional groups on external surfaces of pores of mesoporous silica material |
| CN101966344A (en) * | 2010-10-29 | 2011-02-09 | 中国科学院上海硅酸盐研究所 | Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof |
| CN102070148A (en) * | 2009-11-23 | 2011-05-25 | 哈尔滨理工大学 | Synthesis method and application of mono-disperse micron-scale spherical mesoporous silicon oxide MCM-41 |
| CN102380102A (en) * | 2011-11-02 | 2012-03-21 | 东华大学 | Method for preparing environment-responsive mesoporous silicon nanoparticles |
| CN102786061A (en) * | 2012-07-20 | 2012-11-21 | 东华大学 | Preparation method of hollow mesoporous silica nanoparticle |
-
2014
- 2014-04-29 CN CN201410181123.XA patent/CN103990177A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721751A (en) * | 2008-10-10 | 2010-06-09 | 张阳德 | Human tissue engineering support loaded with controlled-release cell growth factor and provided with hollow silicon dioxide ball with kernel and preparation method and applications thereof |
| CN101721970A (en) * | 2008-10-22 | 2010-06-09 | 中国科学院大连化学物理研究所 | Method for preparing modification functional groups on external surfaces of pores of mesoporous silica material |
| CN102070148A (en) * | 2009-11-23 | 2011-05-25 | 哈尔滨理工大学 | Synthesis method and application of mono-disperse micron-scale spherical mesoporous silicon oxide MCM-41 |
| CN101966344A (en) * | 2010-10-29 | 2011-02-09 | 中国科学院上海硅酸盐研究所 | Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof |
| CN102380102A (en) * | 2011-11-02 | 2012-03-21 | 东华大学 | Method for preparing environment-responsive mesoporous silicon nanoparticles |
| CN102786061A (en) * | 2012-07-20 | 2012-11-21 | 东华大学 | Preparation method of hollow mesoporous silica nanoparticle |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106519558A (en) * | 2016-10-11 | 2017-03-22 | 天津大学 | Preparation and application of imidozalium salt type polyether ether ketone/functionalized mesoporous silicon hybrid membrane |
| CN106519558B (en) * | 2016-10-11 | 2019-01-18 | 天津大学 | Imidazoles salt form polyether-ether-ketone/functional mesoporous silicon hybridization film preparation and application |
| CN106729941A (en) * | 2017-03-07 | 2017-05-31 | 南京林业大学 | A kind of preparation method of chitosan-based sponge dressing |
| CN106806939A (en) * | 2017-03-29 | 2017-06-09 | 中国人民解放军国防科学技术大学 | Bone renovating material and its preparation method and application |
| CN106806939B (en) * | 2017-03-29 | 2020-03-31 | 中国人民解放军国防科学技术大学 | Bone repair material and preparation method and application thereof |
| CN110433331A (en) * | 2019-08-26 | 2019-11-12 | 四川大学 | A kind of bioactive bracket and preparation method thereof |
| CN110433331B (en) * | 2019-08-26 | 2021-08-24 | 四川大学 | Bioactive scaffold and preparation method thereof |
| CN115010904A (en) * | 2022-07-04 | 2022-09-06 | 青岛爱尔家佳新材料股份有限公司 | Organosilicon modified waterborne epoxy emulsion, waterborne epoxy primer and preparation method thereof |
| CN115010904B (en) * | 2022-07-04 | 2023-12-19 | 青岛爱尔家佳新材料股份有限公司 | Organosilicon modified aqueous epoxy emulsion, aqueous epoxy primer and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103990177A (en) | Preparation method for mesoporous-silicon medicine-carrying system modified by bone-morphogenetic-protein active polypeptide | |
| Claaßen et al. | Quantification of substitution of gelatin methacryloyl: best practice and current pitfalls | |
| Lee et al. | Injectable hydrogel composite containing modified gold nanoparticles: implication in bone tissue regeneration | |
| EP3368085B1 (en) | Modified alginates for anti-fibrotic materials and applications | |
| US20220380488A1 (en) | Ultra-low molecular weight hyaluronic acid and preparation method therefor | |
| JP6143269B2 (en) | Self-assembled composite ultra-small peptide polymer hydrogel | |
| Huo et al. | Self‐Assembling Peptide‐Based Functional Biomaterials | |
| CN101835493A (en) | Amphipathic nature polyalcohol and belong to complex between the BMP of BMP family | |
| CN101903408A (en) | Chitosan composition | |
| Mahmoud et al. | Role of nanoparticles in osteogenic differentiation of bone marrow mesenchymal stem cells | |
| JPWO2004046200A1 (en) | Drug sustained-release carrier | |
| CN110613844A (en) | Mini combined adjuvant nanoparticle and preparation method and application thereof | |
| Kim et al. | Thermo-responsive human α-elastin self-assembled nanoparticles for protein delivery | |
| WO2023155861A1 (en) | Aluminum nanocrystalline composite immune drug and preparation method therefor and use thereof | |
| Acar et al. | Chondro-inductive hyaluronic acid/chitosan coacervate-based scaffolds for cartilage tissue engineering | |
| JP5769143B2 (en) | Cell culture substrate | |
| CN114149965A (en) | Preparation method of ultrapure fresh and live exosome | |
| CN108341976A (en) | The derivative and synthetic method of methyl-prop alkylene host material based on click chemistry | |
| Deng et al. | Biotin–Avidin System-Based Delivery Enhances the Therapeutic Performance of MSC-Derived Exosomes | |
| Hou et al. | Cartilage tissue-mimetic pellets with multifunctional magnetic hyaluronic acid-graft-amphiphilic gelatin microcapsules for chondrogenic stimulation | |
| CN110496229B (en) | Nanoparticle-coated antibacterial peptide with slow release property and preparation method thereof | |
| Terauchi et al. | Cyclodextrin-based supramolecular complexes of osteoinductive agents for dental tissue regeneration | |
| CN114854045A (en) | Polyamino acid hydrogel and preparation method and application thereof | |
| CN113440620A (en) | Up-conversion nanoparticles and application thereof in light-operated induced MSC cartilage differentiation and tracing imaging | |
| WO2021196490A1 (en) | Nucleic acid-calcium phosphate nanoparticle complex and application thereof in biomineralization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140820 |